ADVFN US – Market Content Editor

Wanderport is preparing an early beta launch of its AI-powered Issuer Works platform while pursuing debt restructuring, physical AI opportunities and potential strategic acquisitions. Key Investor Takeaways Why WDRP Stock Is in Focus Wanderport provided an update covering its AI product strategy, the approaching beta launch of Issuer Works and planned changes to its capital…

The FDA has accepted fenebrutinib for priority review across two forms of multiple sclerosis following three Phase III studies, moving Roche toward a potential expansion of its MS portfolio beyond Ocrevus. Key Investor Takeaways Why RHHBY Stock Is in Focus Genentech said the FDA has accepted its New Drug Application for fenebrutinib under priority review…

Frequency Holdings has begun using ReachOut Digital Intelligence’s new Capchase Pay facility, converting a multi-year customer agreement into upfront cash without issuing equity or adding debt at the parent-company level. Key Investor Takeaways Why FRQN Stock Is in Focus Frequency Holdings has activated the $5 million financing capacity secured by its wholly owned ReachOut Digital…

Rademikibart significantly reduced treatment failure and new moderate-to-severe COPD exacerbations in the Seabreeze STAT study, while Connect Biopharma said it plans to discuss a Phase 3 registrational program with the FDA. Key Investor Takeaways Why CNTB Stock Is in Focus Connect Biopharma reported preliminary topline results from its randomized, double-blind, placebo-controlled Phase 2 Seabreeze STAT…

Sono-Tek’s largest aggregate customer order to date covers 10 production-scale coating systems, adding to more than $10.79 million of backlog across two major programs expected primarily to ship during fiscal 2028. Key Investor Takeaways Why SOTK Stock Is in Focus Sono-Tek has secured approximately $7.19 million of orders from an existing clean energy customer, comprising…

Valion Bio and Shear Kershman Laboratories have completed formulation work for oral mucosal Entolimod, with the next study set to determine whether the needle-free approach can deliver measurable levels of the biologic into the bloodstream. Key Investor Takeaways Why VBIO Stock Is in Focus Valion Bio and Shear Kershman Laboratories have completed the formulation stage…

DarkIris is preparing its AI-powered film production platform for international launch while building a North American operating presence and extending its technology into interactive entertainment. Key Investor Takeaways Why DKI Stock Is in Focus DarkIris is moving closer to the international launch of Cine3.AI while establishing the commercial infrastructure intended to support its expansion into…

Silexion Therapeutics has moved SIL204 into active patient treatment, beginning a multinational Phase 2/3 study that will evaluate the RNAi candidate alongside standard chemotherapy in locally advanced pancreatic cancer. Key Investor Takeaways Why SLXN Stock Is in Focus Silexion has dosed the first patient worldwide in its Phase 2/3 clinical trial of SIL204, marking the…

The pool and spa retailer has entered a lender-backed restructuring that would cut about $685 million of funded debt, bring in new financing and shift majority ownership to existing lenders. Key Investor Takeaways Why LESL Stock Is in Focus Leslie’s has initiated a prearranged Chapter 11 restructuring designed to reduce its debt burden, secure additional…